New pharmacological approaches to atrial fibrillation

Atrial fibrillation (AF) is the most common cardiac arrhythmia facing physicians, afflicting 13% of men and 11% of women over 85 years of age. Epidemiological studies estimate that there are ≥11 million AF sufferers in the seven major economies and that its prevalence will increase two- to threefold...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2012-07, Vol.17 (13-14), p.654-659
Main Authors: Milnes, James T., Madge, David J., Ford, John W.
Format: Article
Language:English
Subjects:
Animals
Anti-Arrhythmia Agents - administration & dosage
Anti-Arrhythmia Agents - adverse effects
Anti-Arrhythmia Agents - pharmacology
Anti-Arrhythmia Agents - therapeutic use
Atrial Fibrillation - drug therapy
Atrial Fibrillation - metabolism
Atrial Fibrillation - physiopathology
Biological and medical sciences
Clinical Trials as Topic
Drug Discovery
General pharmacology
Heart Rate - drug effects
Humans
Ion Channels - metabolism
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atrial fibrillation (AF) is the most common cardiac arrhythmia facing physicians, afflicting 13% of men and 11% of women over 85 years of age. Epidemiological studies estimate that there are ≥11 million AF sufferers in the seven major economies and that its prevalence will increase two- to threefold over the next 50 years. Current strategies for treating AF involve either sinus rhythm (SR) maintenance or heart rate control, combined with anticoagulation therapy. Although SR control is the preferred and most effective treatment of AF, none of the SR control drugs currently available are able to maintain rhythm without significant side effects. In this article we discuss some of the recent advancements in developing new antiarrhythmic drugs for AF.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2012.02.007